---

Market Overview

---

The global market for axial spondyloarthritis is estimated to have been valued at $1,874 million in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 13.44% and reach $7,938 million by 2032. The growth in this market is expected to be driven by several factors, including the introduction of new products, increased awareness about the disease, and higher investments in research and development.

The pharmaceutical industry’s growing interest in the therapeutic potential of treating axial spondyloarthritis has played a significant role in advancing the global market. Although most existing treatments focus on anti-tumor necrosis factor therapy and anti-interleukin 17 therapy, there is increasing anticipation for the use of anti-janus kinase therapy due to its ability to address complex medical needs and challenging targets.

The global axial spondyloarthritis market is well-established, and biopharmaceutical companies are actively seeking to incorporate new technologies into their operations to improve the entire process, from drug discovery to commercialization. These companies are increasingly focusing on biologics and personalized therapy to enhance treatment options and improve patient outcomes. Major players in the market, such as AbbVie Inc., Eli Lilly and Company, Novartis International AG, and Pfizer Inc., are heavily investing in clinical trials for their respective therapeutic candidates targeting axial spondyloarthritis. Increased investment in research and development of drug manufacturing presents significant opportunities in the global market.

With a growing global focus on the treatment of axial spondyloarthritis, major market players are developing novel therapeutics, such as anti-janus kinase therapy, anti-interleukin therapy, and anti-tumor necrosis factor therapy. This development significantly impacts the growth of the axial spondyloarthritis market. The introduction of tumor necrosis factor inhibitors and interleukin 17 inhibitors has marked a new era of drug therapy for previously incurable diseases. For example, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products—Xeljanz, Taltz, and Cosentyx—for treating patients with axial spondyloarthritis.

Countries such as the U.S., Germany, and the U.K. are at the forefront of drug development for axial spondyloarthritis. The presence of major market players in these countries, including UCB S.A., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Eli Lilly and Company, and Novartis International AG, has a positive impact on the market’s growth in these regions.

The COVID-19 pandemic has posed significant challenges to the research and clinical development of emerging therapies for axial spondyloarthritis. Companies operating in this field have shifted their focus to the research and development of drugs for COVID-19 treatment, aligning with global efforts to combat the pandemic. This shift has resulted in delayed launches of emerging therapies and diverted financial resources towards COVID-19-related projects. Consequently, the development and launch of therapies for axial spondyloarthritis, such as ankylosing spondylitis and non-radiographic axial spondyloarthritis, have been impacted.

The production and supply of axial spondyloarthritis therapies have also been significantly disrupted by the COVID-19 pandemic. Lockdown measures imposed by governments worldwide hampered commercial operations, leading to transportation bans. These restrictions negatively impacted the revenue generated from therapy commercialization. Limited access to emerging therapies used to treat axial spondyloarthritis was another consequence of the pandemic.

Furthermore, the COVID-19 outbreak has slowed down clinical trials, primarily due to difficulties in recruiting patients. The timelines for drug launches have been affected as a result. Many healthcare conferences and marketing activities shifted to virtual platforms, and organizations like CDC and ASCO advised against in-person clinical visits.

However, with the relaxation of restrictions and the gradual resumption of transportation activities in the second quarter of 2020, the market for axial spondyloarthritis has gained momentum and is expected to grow during the forecast period of 2022-2032.

---

Market Segmentation

---

The market is segmented based on various factors, including commercialized therapies, potential pipeline products, indication, and region.

Segmentation by Commercialized Therapies
Anti-Tumor Necrosis Factor (TNF) Therapy
Anti-Interleukin (IL) Therapy
Anti-Janus Kinase (JAK) Therapy

Segmentation by Potential Pipeline Products
Anti-Janus Kinase (JAK) Therapy
Anti-Interleukin (IL)-17 Therapy
Other Therapy

Segmentation by Indication
Ankylosing Spondylitis
Non-Radiographic Axial Spondyloarthritis

Segmentation by Country
U.S.
Germany
France
U.K.
Italy
Spain
Japan

The commercialized therapies segment of the global axial spondyloarthritis market was dominated by the anti-tumor necrosis factor therapy in 2021. This segment has witnessed significant innovations over the years, showing great potential in treating various forms of axial spondyloarthritis. It is projected that the commercialized therapies segment will reach $5,041 million by 2032, growing at a compound annual growth rate (CAGR) of 8.40% during the forecast period of 2022-2032. The revenue from commercialized therapies includes contributions from anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) 17 therapy, and anti-janus kinase (JAK) therapy products, which are commercialized to treat different types of axial spondyloarthritis. Factors such as the potential of novel pipeline drugs, advancements in chemical technologies, the success of commercialized therapies, innovative route of administration, rising prevalence of axial spondyloarthritis, and favorable regulatory environment are expected to drive the global axial spondyloarthritis market during the forecast period.

By 2032, the global axial spondyloarthritis market is estimated to be dominated by the anti-interleukin 17 therapy segment, accounting for a 39.49% share of the total potential pipeline products. Other therapies in the pipeline include anti-Granulocyte/macrophage colony stimulating factor (GM-CSF) therapy and anti-phosphodiesterase 4 (PDE4) therapy. In 2032, the anti-janus kinase therapy segment is predicted to hold a 33.89% share, while the other therapy segment is expected to hold a 26.62% share.

In 2021, the ankylosing spondyloarthritis segment held the largest share of the global axial spondyloarthritis market due to a higher number of product approvals in major countries compared to non-radiographic axial spondyloarthritis. This segment accounted for 73.97% of the market in 2021 and is projected to reach $3,787 million by 2032, growing at a CAGR of 8.99% during the forecast period.

The United States is the leading contributor to the axial spondyloarthritis market, with a value of $1,231 million in 2021. The growth in this market can be attributed to increased research and development activities in the country. Key players in the U.S. axial spondyloarthritis market include UCB S.A., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Eli Lilly and Company, Novartis International AG, among others.

---

Competitive Landscape

---

The selection of profiled companies is based on inputs collected from primary experts, as well as an analysis of company coverage, product portfolio, and market penetration.

Key companies profiled in this report include Public companies include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and UCB S.A. The private company profiled is FunPep Co., Ltd.

---

Recent Industry Developments

---

In December 2020, AbbVie’s Upadacitinib (RINVOQ) successfully achieved both primary and secondary endpoints in a Phase III study conducted for the treatment of non-radiographic axial spondyloarthritis.

In August 2020, AbbVie, Inc. submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for RINVOQ (Upadacitinib) as a treatment for adult patients with active ankylosing spondylitis.

In March 2020, Novartis International AG received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) endorsing the use of Cosentyx for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA).

In June 20219, Kyowa Hakko Kirin Co., Ltd. announced positive results from a 16-week efficacy and safety analysis of their Phase 3 study of Brodalumab in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.

---

Key Questions Answered

---

What are the major drivers, challenges, and opportunities in the global market for axial spondyloarthritis?

What are the underlying factors contributing to the emerging trends in the global market for axial spondyloarthritis?

How has the COVID-19 pandemic impacted the overall ecosystem of the global axial spondyloarthritis market?

What are the key development strategies being implemented by major players to maintain their competitiveness in the market?

What is the pricing and reimbursement landscape in the field of axial spondyloarthritis?

What potential therapies are currently in the pipeline for the treatment of axial spondyloarthritis?

What are the regulatory implications in major geographical regions concerning axial spondyloarthritis?

What entry barriers might companies face when entering specific countries?

How is each market segment expected to grow during the forecast period of 2022-2032, and what revenue is anticipated for each segment?

What growth opportunities exist for companies operating in their respective countries?

Who are the leading players that offer significant products or services in the global axial spondyloarthritis market?

Which companies are expected to be highly disruptive in the future, and what are the reasons behind this anticipation?